<DOC>
	<DOCNO>NCT00036790</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Motexafin gadolinium may increase effectiveness doxorubicin make tumor cell sensitive drug . PURPOSE : Phase I trial study effectiveness combine motexafin gadolinium doxorubicin treat patient recurrent metastatic cancer .</brief_summary>
	<brief_title>Motexafin Gadolinium Doxorubicin Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose motexafin gadolinium doxorubicin patient advanced malignancy . - Determine dose-limiting toxicity regimen patient . - Determine safety tolerability regimen patient . - Determine pharmacokinetics regimen patient . - Evaluate tumor response patient treat regimen . OUTLINE : This dose-escalation , multicenter study . Patients assign 1 2 group . Group A : - Course 1 : Patients receive motexafin gadolinium IV 30 minute day 1 , 8 , 9 , 10 doxorubicin IV 15 minute day 8 . - Course 2 : 28 day begin course 1 , patient receive doxorubicin IV 15 minute . - Courses 3-6 : Beginning 21 day course 2 , patient receive doxorubicin IV 15 minute day 1 motexafin gadolinium IV 30 minute day 1-3 . Treatment repeat every 21 day . Group B : - Course 1 : Patients receive motexafin gadolinium IV 30 minute day 1 doxorubicin IV 15 minute day 8 . - Course 2 : 28 day begin course 1 , patient receive doxorubicin IV 15 minute day 1 motexafin gadolinium IV 30 minute day 1-3 . - Courses 3-6 : Beginning 21 day course 2 , patient receive doxorubicin motexafin gadolinium group A . Treatment group continue 6 course absence disease progression , unacceptable toxicity , cumulative doxorubicin dose 450 mg/m^2 . Cohorts 3-6 patient receive escalate dos doxorubicin motexafin gadolinium maximum tolerate dose ( MTD ) determine . The MTD define high dose 0 3 1 6 patient experience dose-limiting toxicity . Patients follow 1 2 month . PROJECTED ACCRUAL : A total 3-48 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced malignancy consider incurable Recurrent metastatic disease Relapsed solid tumor include , limited follow site : Lung Breast Colon Prostate Head neck Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex Not specify Menopausal status Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF great 45 % rest No prior myocardial infarction No congestive heart failure No clinically significant ventricular arrhythmia Other : No history HIV infection No history porphyria No glucose6phosphate dehydrogenase deficiency Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 28 day since prior chemotherapy No prior lifetime cumulative doxorubicin exposure 300 mg/m^2 No concurrent cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 28 day since prior radiotherapy No concurrent radiotherapy Surgery : No concurrent surgery Other : At least 14 day since prior multidrug resistancemodulating drug ( e.g. , PSC833 cyclosporine ) No concurrent antineoplastic investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent lip oral cavity cancer</keyword>
	<keyword>stage III lip oral cavity cancer</keyword>
	<keyword>stage IV lip oral cavity cancer</keyword>
	<keyword>recurrent paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage III paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage IV paranasal sinus nasal cavity cancer</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage III hypopharyngeal cancer</keyword>
	<keyword>stage IV hypopharyngeal cancer</keyword>
	<keyword>recurrent laryngeal cancer</keyword>
	<keyword>stage III laryngeal cancer</keyword>
	<keyword>stage IV laryngeal cancer</keyword>
	<keyword>recurrent oropharyngeal cancer</keyword>
	<keyword>stage III oropharyngeal cancer</keyword>
	<keyword>stage IV oropharyngeal cancer</keyword>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>